A modified laparoscopic sleeve gastrectomy for the treatment of diabetes mellitus type 2 and metabolic syndrome in obesity


Autoria(s): Pirolla, Eduardo H.; Jureidini, Ricardo; Barbosa, Mario L.; Ishikawa, Luis C.; Camargo, Paulo R.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

06/11/2013

06/11/2013

2012

Resumo

BACKGROUND: Ghrelin is a gastrointestinal peptide hormone (a 28-amino acid peptide) produced primarily by X/A cells in the oxyntic glands of the stomach fundus and cells lining the duodenum cavern. It suppresses insulin secretion and action and commands a significant role in regulating food intake. The aim of the present study was to show that modified laparoscopic sleeve gastrectomy (MLSG), in which a significant part of the gastric fundus and body of the stomach is removed up to 1 inch from the pylorus vein, may contribute to decreasing circulating ghrelin levels. METHODS: A study population consisting of 150 individuals was monitored after undergoing a MLSG, with individuals chosen based on a documented history of diabetes mellitus type 2 and metabolic syndrome, clinical results determining a body mass index (BMI) of 35 to 60 kg/m(2), peptide C level greater than 1, negative anti-glutamic acid decarboxylase, negative anti-insulin, and confirmed stability of drug/insulin treatment and glycosylated hemoglobin greater than 6.5% for at least 24 and 3 months, respectively, before enrollment. RESULTS: Twenty-four months after surgery, 150 patients (86.6%) presented with normal glycemic levels between 77 and 99 mg/dL. All patients improved average serum insulin levels by 9 mU/L and average glycosylated hemoglobin levels by 5.1% (normal range, 4%-6%). All patients tested negative for Helicobacter pylori and stopped using insulin, with 3 patients prescribed twice-daily use of an oral hypoglycemiant. In 14% of cases, patients experienced partial hair loss with low serum zinc levels and were prescribed oral zinc reposition and topical hair stimulants. The average weight loss recorded was 44.6% for patients with a BMI less than 45 kg/m(2) and 58% for patients with a BMI greater than 50 kg/m(2). CONCLUSIONS: The MLSG is a safe procedure with a low morbidity rate (2.7%) (4 cases of fistula and 2 of bleeding) and no surgical mortality in this study. This surgery can promote control of diabetes mellitus type 2 and aid the treatment of exogenous overweight and morbidly obese individuals. The results of this study show that only through resection of the ghrelin-producing gastric area can most obesity cases and diabetes type II conditions be reverted to nonobese and controlled diabetes. (c) 2012 Elsevier Inc. All rights reserved.

Identificador

AMERICAN JOURNAL OF SURGERY, BRIDGEWATER, v. 203, n. 6, supl. 1, Part 4, pp. 785-792, JUN, 2012

0002-9610

http://www.producao.usp.br/handle/BDPI/42620

10.1016/j.amjsurg.2011.08.014

http://dx.doi.org/10.1016/j.amjsurg.2011.08.014

Idioma(s)

eng

Publicador

EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC

BRIDGEWATER

Relação

AMERICAN JOURNAL OF SURGERY

Direitos

closedAccess

Copyright EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC

Palavras-Chave #GHRELIN #MODIFIED SLEEVE GASTRECTOMY #DIABETES II #OBESITY #PLASMA GHRELIN LEVELS #WEIGHT-LOSS #BARIATRIC SURGERY #FOOD-INTAKE #CIRCULATING GHRELIN #GASTRIC BYPASS #BODY-FAT #RISK #HUMANS #RATS #SURGERY
Tipo

article

original article

publishedVersion